.png){kind=icon}
.png){kind=icon}
Return
Indication-specific use of Denosumab in Giant Cell Tumour of Bone: A retrospective cohort study
.png){kind=icon}
OA
AI
M
V
G
M
L
F
DOI：10.1016/j.ejso.2026.111979.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Long-term Denosumab is an effective treatment option for selected GCTB patients. • A clinical framework for indication specific Denosumab use in GCTB patients to support physicians with informed treatment decision. • Prolonged disease control was frequently achieved in definitive Denosumab treatment often allowing dose de-escalation.
Keywords:
Giant cell tumours of bone (GCTB)
Denosumab
Local recurrence
Long-term treatment
Treatment indications
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
2.9
Papers:
6.7K
Citations:
1.3W
Organization
Cited Papers